Market Overview

The global Medical Cyclotron Market was valued at USD 247.5 Million in 2024. The market is forecasted to grow at a CAGR of 7.22% during 2025-2033 to reach USD 478.3 Million by 2033. Growth is driven by rising demand for PET diagnostic scans, increasing cancer and cardiovascular diseases, technological advancements in radiopharmaceuticals, expanding healthcare infrastructure, and supportive government initiatives promoting nuclear medicine and diagnostic imaging.

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Medical Cyclotron Market Key Takeaways

• The global medical cyclotron market size was USD 247.5 Million in 2024 and is projected to reach USD 478.3 Million by 2033.
• The market is expected to grow at a CAGR of 7.22% during 2025-2033.
• Asia Pacific dominated the market in 2024.
• Increasing prevalence of cancer and chronic diseases is boosting the demand for medical cyclotrons, as PET scans require radioisotopes produced by cyclotrons.
• Advancements in radiopharmaceuticals and integration of AI and machine learning in research are expanding diagnostic and therapeutic applications.
• Expanding healthcare infrastructure, particularly in emerging economies like India, and supportive government policies enhance market growth.

Sample Request Link: https://www.imarcgroup.com/medical-cyclotron-market/requestsample

Market Growth Factors

Growing demand for diagnostic imaging procedures such as PET scans is expected to increase the global medical cyclotron market at a meaningful rate. The rising incidence of cancer and cardiovascular diseases worldwide is expected to increase the need for early and precise diagnosis of these diseases, thus driving market growth. Furthermore, the National Cancer Institute predicts that in 2025 there will be over 2 million new cancer patients in the United States, and improvements in radiopharmaceuticals and imaging techniques provide an impetus for industrial cyclotron systems worldwide.

One of the major drivers of this market is the advancement of radiopharmaceuticals, with an estimated global market value of USD 5.8 Billion in 2024, a compound annual growth rate (CAGR) of 4.9%, reaching USD 8.9 Billion in 2033. This results in the development of more specific and targeted compounds for both diagnostic and therapeutic applications. The use of artificial intelligence and machine learning in research is speeding up the development of new compounds, which leads to the production of new radioisotopes and increases the market for medical cyclotrons.

Increasing healthcare infrastructure and rising investments in healthcare diagnostic imaging is driving the growth of the market. For instance, as of March 2023, India has 169,615 Sub-Centres and close to 362 Medical Colleges. Growth in the number of PET and PET-CT centers, government support, and investment in nuclear medicine and diagnostic imaging around the globe are among the factors leading to increased access to advanced diagnostic imaging and radiopharmaceuticals for medical cyclotron use.

Market Segmentation

By Type:

• Ring Cyclotron: Dominates due to superior high-energy radioisotope production capabilities for advanced diagnostics like PET, supporting continuous particle acceleration for high yield and consistent radiopharmaceutical supply.
• Azimuthally Varying Field (AVF) Cyclotron: Listed as a category but without additional details provided.

By Product Type:

• Cyclotron 16-18 MeV: Leads the market owing to optimal production capacity and efficiency balance, producing key radioisotopes like Fluorine-18 essential for PET imaging. These cyclotrons offer cost-effectiveness and versatility.
• Cyclotron 10-12 MeV, Cyclotron 19-24 MeV, Cyclotron 24 MeV and Above: Listed but no detailed data found.

By End User:

• Hospitals: Largest market segment, producing essential radioisotopes for PET and SPECT imaging, enhancing timely supply and reducing dependency on external sources.
• Diagnostic Centers, Research and Academic Institutes, Others: Listed but without detailed data.

Regional Insights

Asia Pacific accounted for the largest share in the medical cyclotron market in 2024, driven by robust healthcare infrastructure expansion in countries such as China, Japan, and India. Growing cancer prevalence, increased governmental investments, favorable policies, and the rising adoption of PET imaging bolster regional market dominance. The region also benefits from leading cyclotron manufacturers and increased nuclear medicine R&D activities.

Recent Developments & News

• February 2025: The State Government of Nagpur plans to establish a cyclotron center facilitating early cancer detection and nuclear research for wide industrial applications.
• February 2025: Framatome partnered with IBA to promote manufacturing of the alpha-emitting radioisotope Astatine-211 in the US and Europe, aiming for a reliable network of specialized cyclotrons.
• November 2024: National Institute of Science Education and Research (NISER) in Bhubaneswar announced plans for medical cyclotron facility construction starting March 2025 for isotope production used in PET CT and SPECT-CT scans.
• October 2024: African Medical Centre of Excellence (AMCE) plans to establish a cyclotron facility in Abuja for diagnosing and treating cancer, heart, and neurological conditions.

Key Players

• Advanced Cyclotron Systems Inc.
• Alcen
• Best Medical International Inc.
• General Electric Company
• IBA RadioPharma Solutions
• Ionetix Corporation
• Isosolution Inc.
• Siemens AG
• Sumitomo Heavy Industries Ltd.
• Varian Medical Systems Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request For Customization: https://www.imarcgroup.com/request?type=report&id=4573&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302